免疫靶向疗法时代治疗寡转移性黑色素瘤的方法

E. V. Ledin, V. I. Stolyarov
{"title":"免疫靶向疗法时代治疗寡转移性黑色素瘤的方法","authors":"E. V. Ledin, V. I. Stolyarov","doi":"10.21518/ms2024-236","DOIUrl":null,"url":null,"abstract":"Oligometastatic disease is a term that describes the state of a tumor between a localized tumor and a disseminated process, when all detected tumor lesions are accessible to local action. The concept of oligometastatic disease in advanced cutaneous melanoma has existed since the 1970–1980s, and the role of metastasectomy of solitary lesion is approved in the treatment strategy for this disease. However, the role of local methods before the introduction of modern systemic therapy was quite modest due to the aggressive and often primary disseminated course of the disease. The introduction of immunotherapy and modern targeted therapy in the treatment of metastatic melanoma has significantly increased the number of patients meeting the criteria for oligometastatic disease with the possibility of metastasectomy. Currently, there is no clear algorithm or specific sequence for combining systemic treatment methods with surgical and other local methods. Conditional neoadjuvant immunotherapy is being actively discussed even for primary resectable melanoma metastases; this concept is based on the higher effectiveness of immunotherapy in the presence of tumor tissue in the body and already has practical confirmation from recent studies. In determining the tactics for oligometastatic melanoma, a multidisciplinary approach is extremely important, including a balanced assessment of possible local surgical options, the use of radiotherapy and mandatory systemic disease control. By successfully applying and combining these approaches, it is possible to achieve outstanding success in controlling the disease in a significant proportion of patients. This review provides an analysis of the main and most important works on systemic and surgical treatment of oligometastatic melanoma.","PeriodicalId":18391,"journal":{"name":"Meditsinskiy sovet = Medical Council","volume":"94 10","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Approaches to the treatment of oligometastatic melanoma in the era of immunotargeted therapy\",\"authors\":\"E. V. Ledin, V. I. Stolyarov\",\"doi\":\"10.21518/ms2024-236\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Oligometastatic disease is a term that describes the state of a tumor between a localized tumor and a disseminated process, when all detected tumor lesions are accessible to local action. The concept of oligometastatic disease in advanced cutaneous melanoma has existed since the 1970–1980s, and the role of metastasectomy of solitary lesion is approved in the treatment strategy for this disease. However, the role of local methods before the introduction of modern systemic therapy was quite modest due to the aggressive and often primary disseminated course of the disease. The introduction of immunotherapy and modern targeted therapy in the treatment of metastatic melanoma has significantly increased the number of patients meeting the criteria for oligometastatic disease with the possibility of metastasectomy. Currently, there is no clear algorithm or specific sequence for combining systemic treatment methods with surgical and other local methods. Conditional neoadjuvant immunotherapy is being actively discussed even for primary resectable melanoma metastases; this concept is based on the higher effectiveness of immunotherapy in the presence of tumor tissue in the body and already has practical confirmation from recent studies. In determining the tactics for oligometastatic melanoma, a multidisciplinary approach is extremely important, including a balanced assessment of possible local surgical options, the use of radiotherapy and mandatory systemic disease control. By successfully applying and combining these approaches, it is possible to achieve outstanding success in controlling the disease in a significant proportion of patients. This review provides an analysis of the main and most important works on systemic and surgical treatment of oligometastatic melanoma.\",\"PeriodicalId\":18391,\"journal\":{\"name\":\"Meditsinskiy sovet = Medical Council\",\"volume\":\"94 10\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Meditsinskiy sovet = Medical Council\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21518/ms2024-236\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Meditsinskiy sovet = Medical Council","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21518/ms2024-236","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

寡转移病是指肿瘤介于局部肿瘤和播散过程之间的一种状态,即所有检测到的肿瘤病灶均可在局部发挥作用。晚期皮肤黑色素瘤寡转移病的概念早在 20 世纪 70-80 年代就已存在,单发病灶的转移切除术在该病的治疗策略中被认可。然而,在引入现代系统疗法之前,由于该疾病的侵袭性和经常出现的原发性播散病程,局部方法的作用非常有限。免疫疗法和现代靶向疗法被引入转移性黑色素瘤的治疗后,符合寡转移疾病标准并有可能进行转移灶切除术的患者人数大幅增加。目前,还没有将全身治疗方法与手术和其他局部治疗方法相结合的明确算法或具体顺序。目前正在积极讨论有条件的新辅助免疫疗法,即使是针对可切除的原发性黑色素瘤转移灶;这一概念的依据是,在体内存在肿瘤组织的情况下,免疫疗法的疗效更高,最近的研究已经证实了这一点。在确定治疗少转移黑色素瘤的策略时,多学科方法极为重要,包括对可能的局部手术方案、放疗的使用和强制性全身疾病控制进行平衡评估。通过成功应用和结合这些方法,有可能使相当一部分患者在控制病情方面取得巨大成功。本综述分析了寡转移黑色素瘤全身治疗和手术治疗方面最重要的主要著作。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Approaches to the treatment of oligometastatic melanoma in the era of immunotargeted therapy
Oligometastatic disease is a term that describes the state of a tumor between a localized tumor and a disseminated process, when all detected tumor lesions are accessible to local action. The concept of oligometastatic disease in advanced cutaneous melanoma has existed since the 1970–1980s, and the role of metastasectomy of solitary lesion is approved in the treatment strategy for this disease. However, the role of local methods before the introduction of modern systemic therapy was quite modest due to the aggressive and often primary disseminated course of the disease. The introduction of immunotherapy and modern targeted therapy in the treatment of metastatic melanoma has significantly increased the number of patients meeting the criteria for oligometastatic disease with the possibility of metastasectomy. Currently, there is no clear algorithm or specific sequence for combining systemic treatment methods with surgical and other local methods. Conditional neoadjuvant immunotherapy is being actively discussed even for primary resectable melanoma metastases; this concept is based on the higher effectiveness of immunotherapy in the presence of tumor tissue in the body and already has practical confirmation from recent studies. In determining the tactics for oligometastatic melanoma, a multidisciplinary approach is extremely important, including a balanced assessment of possible local surgical options, the use of radiotherapy and mandatory systemic disease control. By successfully applying and combining these approaches, it is possible to achieve outstanding success in controlling the disease in a significant proportion of patients. This review provides an analysis of the main and most important works on systemic and surgical treatment of oligometastatic melanoma.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信